Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2017

View Archived Issues

Sarepta's phase I/II study of golodirsen in DMD meets primary biological endpoint

GSK exercises option to develop and commercialize SPEAR T-cell therapy program targeting NY-ESO

Phase IIb trial of upadacitinib in atopic dermatitis meets primary endpoint

Intra-Cellular Therapies reports data from first part of lumateperone study

Clinical results presented for JNJ-42847922/MIN-202 in insomnia and major depression

Tyme reports positive results from long-term analysis of SM-88 trial in metastatic cancer

Boehringer Ingelheim and Gubra to develop treatments for obesity

Rutgers University discovers novel chemical entities for treating tuberculosis

Iovance Biotherapeutics and Ohio State University enter preclinical research collaboration

Novartis presents new analyses on AMG-334

FDA awards breakthrough therapy designation to cemiplimab for advanced CSCC

Amylyx Pharmaceuticals enters collaboration with Project ALS

SBIR grant supports Oligomerix's development of Alzheimer's disease specific antibody biomarker

VSV-GP shows promising in vitro results for the treatment of lung cancer

FDA places clinical hold on durvalumab studies

Lyndra and Allergan partner to develop ultra-long-acting Alzheimer's treatment

Alnylam updates status of fitusiran and givosiran development programs

Bristol-Myers Squibb completes acquisition of IFM Therapeutics

miRNAs found to impact MDD treatment response

Shanghai Institute Materia Medica discovers new FGFR inhibitors

Sumitomo Dainippon Pharma generates novel imidazolylamide derivatives

New 5' AMP-activated protein kinase activators discovered at Shionogi & Co.

R-Pharm CJSC presents novel serine/threonine-protein kinase B-raf inhibitors

Asceneuron patents N-acetyl-beta-D-glucosaminidase inhibitors

Eisai and Ono collaborate to develop Lenvima and Opdivo combination for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...